| Original language | English (US) |
|---|---|
| Pages (from-to) | 665-673 |
| Number of pages | 9 |
| Journal | Journal of the American Society of Nephrology |
| Volume | 33 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2022 |
ASJC Scopus subject areas
- Medicine(all)
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Society of Nephrology, Vol. 33, No. 4, 04.2022, p. 665-673.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Premature Death in Kidney Transplant Recipients
T2 - The Time for Trials is Now
AU - Vinson, Amanda J.
AU - Singh, Sunita
AU - Chadban, Steven
AU - Cherney, David
AU - Gaber, Osama
AU - Gill, John S.
AU - Helgeson, Erika
AU - Herzog, Charles A.
AU - Jardine, Meg
AU - Jha, Vivekanand
AU - Kasiske, Bertram L.
AU - Mannon, Roslyn B.
AU - Michos, Erin D.
AU - Mottl, Amy K.
AU - Newby, Kristin
AU - Roy-Chaudhury, Prabir
AU - Sawinski, Deirdre
AU - Sharif, Adnan
AU - Sridhar, Vikas S.
AU - Tuttle, Katherine R.
AU - Vock, David M.
AU - Matas, Arthur
N1 - Funding Information: A. Gaber reports having an ownership interest in financials, technology, and oil companies; reports receiving research funding from Amplyx Therapeutics, Angion, CareDx, Hansa Biopharma Medior Therapeutics, Novartis, Sanofi, and Veloxis; reports receiving honoraria from Optum Health and Sanofi; and reports other interests or relationships as Chairman for Nora’s Life Gift Foundation. A. K. Matas reports receiving honoraria and consulting fees from Bayer and Veloxis; reports receiving research support from Alexion, Aurinia, Boehringer Ingelheim, Calliditas, CareDX, CSL Behring, Pfizer, Shire, and Veloxis; reports receiving honoraria from Bayer and UpToDate; and reports being a scientific advisor or member of Bayer, CareDx, and Jazz. A. Sharif reports having consultancy agreements with Hansa Pharmaceuticals; reports receiving research funding from Chiesi Pharmaceuticals; reports receiving honoraria from Chiesi Pharmaceuticals; reports being a scientific advisor or member of the advisory board meetings for Atara Biotherapeutics, Boehringer Ingelheim/Lilly Alliance, and Novartis Pharmaceuticals; and reports speakers bureau for meetings/symposia hosted by Astellas, Chiesi, and Novartis; and reports receiving funding from Boehringer Ingelheim/Lilly and Napp Pharmaceuticals. A. Vinson reports receiving consultancy and fellowship fees from Paladin Labs Inc. C. Herzog reports employment with Hennepin Healthcare System, Inc.; reports being a consultant for AbbVie, Amgen, AstraZeneca, Bayer, Corvidia, DiaMedica, FibroGen, Janssen, Merck, NxStage, Pfizer, Relypsa, Sanifit, and the University of Oxford; reports having an ownership interest with stock only (no other ownership role) in Boston Scientific, Bristol-Meyers Squibb, General Electric, Johnson & Johnson, Merck, and Pfizer; reports receiving research funding from Amgen, AstraZeneca, Bristol-Meyers Squibb, National Heart, Lung, and Blood Institute (NHLBI)/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (National Institutes of Health [NIH]), Relypsa, and the University of British Columbia; reports receiving honoraria from the American College of Cardiology (non-profit) and UpToDate (writing royalties); reports patents or royalties from UpToDate; reports having an advisory or leadership role with the American Heart Journal Editorial Board; and reports having other interests or relationships as Kidney Disease: Improving Global Outcomes: Planning Committee Co-Chair for the “CKD, Heart, and Vasculature” conference series, and as a participant in various nephrology-related controversies conferences for the ASN (Kidney Health Initiative workgroups). D. Cherney reports receiving honoraria from AbbVie, Astellas, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim-Lilly, CSL-Behring, Janssen, J&J, Maze, Merck, Mitsubishi-Tanabe, Novo-Nordisk, Otsuka, Prom-etic, and Sanofi; and reports receiving operational funding for clinical trials from AstraZeneca, Boehringer Ingelheim-Lilly, Janssen, Merck, Novo-Nordisk, and Sanofi; reports consultancy with AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim-Lilly, CSL Pharma, Janssen, Maze, Merck, Mitsubishi-Tanabe, NovoNordisk, Prom-etic, and Sanofi; and reports an advisory or leadership role with AstraZeneca, Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, and Sanofi. D. Sawinski reports having an ownership interest in CareDx; reports receiving research funding from the NIH; reports being a scientific advisor or member of the American Journal of Kidney Diseases and Clinical Transplantation; and reports having other interests/relationships as a United Network for Organ Sharing Kidney Committee member. E. D. Michos reports serving on the advisory boards for AstraZeneca, Amarin, Bayer, Boehringer Ingelheim, Esperion, Novartis, and Novo Nordisk; and reports being a scientific advisor or member as the Editor in Chief for the American Journal of Preventive Cardiology. J. Gill reports receiving honoraria from Takeda and Veloxis; reports having an advisory or leadership role with the American Society of Transplantation, and the Journal of the American Society of Nephrology; and reports receiving consultancy fees from Astellas and Volexis, and grant support from Astellas. K. Newby reports having consultancy agreements with Beckman-Coulter, Better Therapeutics, GlaxoSmithKline, and Medtronic; reports receiving research funding from the BioKier, Center for Disease Control, NIH (NIA and NHLBI), North Carolina Department of Health and Human Services, and Roche Diagnostics; reports receiving honoraria from Oregon ACC and the NHLBI; and reports being a scientific advisor or member of the AstraZeneca Healthcare Foundation (Board, uncompensated), David H. Murdock Research Institute (Board, uncompensated), and NHLBI Board of External Experts. K. R. Tuttle reports having consultancy agreements with AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Goldfinch Bio, and Novo Nordisk; reports receiving research funding from Bayer, Goldfinch Bio, and Travere; reports receiving honoraria from Bayer, Boehringer Ingelheim, Gilead, and Novo Nordisk; and reports being a scientific advisor or member of CJASN, Kidney Health Initiative, Lancet Diabetes Endocrinology, Nature Reviews Nephrology, and NIDDK. M. J. Jardine is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro, and Merck Sharp & Dohme Corp; has received Advisory, Steering Committee and/or speaker fees from Akebia, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Chinook, CSL, Janssen, Merck, MSD, PeerVoice, Roche, and Vifor; with any consultancy, honoraria, or travel support paid to the institution; and reports being supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship. P. Roy-Chaudhury reports consultancy with WL Gore, Medtronic/ Covidien, BD-Bard, Cormedix, Humacyte, Akebia, Vifor-Relypsa, Bayer, Reata, and InRegen; ownership interest as Chief Scientific Officer and Founder of Inovasc LLC; research funding from NIH Small Business Grants as MPI or site PI with: Inovasc, Adgero, Cylerus and Eko; honoraria from WL Gore, Medtronic/Covidien, BD-Bard, Cormedix, Huma-cyte, Akebia, Vifor-Relypsa, Bayer, Reata, Chugai Pharmaceuticals, and InRegen; advisory or leadership role with ASN, Cardiorenal Society, Vascular Access Society of the America's, WL Gore, Med-tronic/Covidien, BD-Bard, Cormedix, Humacyte, Akebia, Vifor-Relypsa, Bayer, Reata, InRegen, and Editorial Board of Journal of Vascular Access; and other interests or relationships - discussions with: Vasbio, Elucid Bio, and Outset Medical, and Research Contract while at University of Arizona with Kidney Research Institute Seattle. R. B. Mannon reports receiving grant funding from Verici Diagnostic; reports being a member of the Steering Committees for CSL-Behring IMAGINE Trial and Verici Diagnostics VDX20-1001 Study; reports receiving research funding from Astellas, CareDx, CSL Behring, Mallinckrodt, Quark Pharmaceuticals, and Transplant Genomics, Inc.; reports receiving honoraria from CSL Behring, Hansa, Novartis, Sanofi, and Vitaerris; reports patents and inventions with Eurofins; and reports other interests/relationships as the ASN Grants committee Chair, ASN Policy and Advocacy Committee, Chair Data Safety Monitoring Board, Chair Women in Transplantation, Co-Chair Scientific Registry of Transplant Recipients Review Committee, NIDDK/NIH, and Program Committee the Transplantation Society 2020, 2022. S. J. Chadban reports having a consultancy with CSL; reports receiving research funding from Baxter payments made to hospital, CSL, and Novartis; reports receiving honoraria from AstraZeneca and Novartis; and reports having an advisory or leadership role with CSL and Novartis. S. K. Singh reports receiving a drug supply from AstraZeneca for an investigator-initiated study (NCT04965935). V. Jha reports receiving grant funding from Baxter Healthcare, Biocon, and GSK; and reports receiving honoraria from AstraZeneca, Baxter, Boehringer Ingelheim, Nephro-Plus, and Zydus Cadilla, under the policy of all honoraria being paid to the organization. All remaining authors have nothing to disclose.
PY - 2022/4
Y1 - 2022/4
UR - http://www.scopus.com/inward/record.url?scp=85128001651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128001651&partnerID=8YFLogxK
U2 - 10.1681/ASN.2021111517
DO - 10.1681/ASN.2021111517
M3 - Article
C2 - 35292438
AN - SCOPUS:85128001651
SN - 1046-6673
VL - 33
SP - 665
EP - 673
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 4
ER -